Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now full pipeline

Hyperlipidemias: full-pipeline trial registry

6 of 22 indexed Hyperlipidemias trials are currently recruiting.

Corpus placement: #756 of 28,707 conditions by registered trial count.

22 US clinical trials · 6 currently recruiting · #756 of 28,707 conditions by registered trial count

Hyperlipidemias: 22 US clinical trials tracked, 6 recruiting.

Hyperlipidemias is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins University, running 2 of these trials.

Enrollment posture brief

Registry condition hyperlipidemias

OPEN 6 | RECR 27% | LATE 2 | EARLY 3 | RANK #756 | SPON 2

Nearest open-share peer: Atherosclerotic Cardiovascular Disease (27% recruiting · 22 trials)

Advanced Melanoma63.6%Hyperlipidemias (this)27%Acute Myeloid Leukemia Arisi18.2%Adenocarcinoma of the Prosta0%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Hyperlipidemias

Hyperlipidemias lists 6 open slots (27% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hyperlipidemias on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hyperlipidemias is recruiting below its size-band peers.

    6 of 22 indexed trials (27.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Hyperlipidemias trials is spread across many organizations.

    Johns Hopkins University accounts for 2 of 22 trials (9.1%). 20 distinct sponsors appear on at least one study for this condition label.

  3. Typical Hyperlipidemias enrolment sits around 87 participants.

    Median target enrolment is 87 among the 22 trials that report a genuine target (sentinel values excluded). 13 of those (59.1%) plan for fewer than 100 participants.

  4. Hyperlipidemias research is mostly interventional.

    20 interventional and 2 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22Phase 31Phase 41

Open and recent trials

22 total, page 1 of 1

RECRUITING NA 68,000 participants

Social Needs Screening and Chronic Diseases Study (WE CARE)

University of Massachusetts, Worcester

NCT06903897

RECRUITING NA 1,980 participants

Penn Medicine Healthy Heart

University of Pennsylvania

NCT06062394

RECRUITING NA 340 participants

Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention

Ohio State University

NCT06055036

RECRUITING NA 95 participants

Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients

West Virginia School of Osteopathic Medicine

NCT06049420

RECRUITING 50 participants

Imaging the Pathogenesis of Cerebral Small Vessel Disease

Johns Hopkins University

NCT05703386

RECRUITING 20 participants

Bempedoic Acid Pregnancy Surveillance Program

Esperion Therapeutics

NCT05103254

ACTIVE NOT RECRUITING NA 1,950 participants

Centralized Prescribing for Statins

University of Pennsylvania

NCT05537064

ACTIVE NOT RECRUITING NA 1,000 participants

Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)

Johns Hopkins University

NCT06347484

ACTIVE NOT RECRUITING Phase 2 720 participants

Virtual Diabetes Group Visits Across Health Systems

University of Chicago

NCT06094491

ACTIVE NOT RECRUITING NA 37 participants

Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome

Rutgers, The State University of New Jersey

NCT06461273

COMPLETED NA 9,501 participants

Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications

University of Colorado, Denver

NCT03973931

COMPLETED NA 298 participants

A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention

Case Western Reserve University

NCT03643705

COMPLETED Phase 3 144 participants

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Kastle Therapeutics

NCT00694109

COMPLETED NA 87 participants

Pilot Study on the Effects of a Plant-Strong Diet on Cardiovascular Risk Factors

Phoenix VA Health Care System

NCT03330548

COMPLETED Phase 1 70 participants

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

Silence Therapeutics

NCT04606602

COMPLETED NA 41 participants

Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children

Poudre Valley Health System

NCT01911390

COMPLETED NA 30 participants

Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers

Tufts University

NCT00175084

COMPLETED Phase 4 26 participants

Effects of Psyllium on Niacin Tolerability

VA Greater Los Angeles Healthcare System

NCT03370848

COMPLETED NA 20 participants

Food Pharmacy at Oregon Health & Science University (OHSU) Knight Cardiovascular Institute (KCVI)

Oregon Health and Science University

NCT04036773

COMPLETED Phase 2 16 participants

Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia

Catabasis Pharmaceuticals

NCT01968720

COMPLETED NA 11 participants

The Mixed Meal Challenge Study

Emory University

NCT05087823

COMPLETED NA 9 participants

Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness

Katherine Vickery

NCT06025721

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Hyperlipidemias records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
Bean powder and rice bran Dietary supplement
1 trials
Control arm Dietary supplement
1 trials
Rice bran Dietary supplement
1 trials
Bean powder Dietary supplement
1 trials
Mixed Meal Challenge Dietary supplement
1 trials
Glucose Challenge Dietary supplement
1 trials
Lipid Challenge Dietary supplement
1 trials

US sites by state

Facility locations filed on Hyperlipidemias trials. A trial with sites in several states counts in each.

Ohio 5 trials
North Carolina 3 trials
Massachusetts 3 trials
Florida 3 trials
Pennsylvania 2 trials
Oregon 2 trials
Maine 2 trials
Maryland 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hyperlipidemias page

22 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hyperlipidemias condition card totals 22 registered trials; most-linked intervention Placebo; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.